TerminatedEarly Phase 1NCT06056596

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Wisconsin, Madison
Principal Investigator
Michael Altaweel, MD
University of Wisconsin, Madison
Intervention
Lamivudine 300 MG(drug)
Enrollment
2 target
Eligibility
18-75 years · All sexes
Timeline
20242024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06056596 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials